Cell-specific expression of neuropeptide Y Y1 receptor immunoreactivity in the rat basolateral amygdala.
Activation of neuropeptide Y (NPY) Y1 receptors (Y1r) in the rat basolateral nuclear complex of the amygdala (BLA) produces anxiolysis and interferes with the generation of conditioned fear. NPY is important in regulating the output of the BLA, yet the cell types involved in mediating this response are currently unknown. The current studies employed multiple label immunocytochemistry to determine the distribution of Y1r-immunoreactivity (-ir) in glutamatergic pyramidal and GABAergic cell populations in the BLA using scanning laser confocal stereology. Pyramidal neurons were identified by expression of calcium-calmodulin dependent kinase II (CaMKII-ir) and functionally distinct interneuron subpopulations were distinguished by peptide (cholecystokinin, somatostatin) or calcium-binding protein (parvalbumin, calretinin) content. Throughout the BLA, Y1r-ir was predominately on soma with negligible fiber staining. The high degree of coexpression of Y1r-ir (99.9%) in CaMKII-ir cells suggests that these receptors colocalize on pyramidal cells and that NPY could influence BLA output by directly regulating the activity of these projection neurons. Additionally, Y1r-ir was also colocalized with the interneuronal markers studied. Parvalbumin-ir interneurons, which participate in feedforward inhibition of BLA pyramidal cells, represented the largest number of Y1r expressing interneurons in the BLA ( approximately 4% of the total neuronal population). The anatomical localization of NPY receptors on different cell populations within the BLA provides a testable circuit whereby NPY could modulate the activity of the BLA via actions on both projection cells and interneuronal cell populations.
Rostkowski
Amanda B
AB
Department of Neuroscience, Chicago Medical School/Rosalind Franklin University of Medicine and Science, North Chicago, Illinois 60064, USA.
Teppen
Tara L
TL
Peterson
Daniel A
DA
Urban
Janice H
JH
D000679:Amygdala / Q000166:cytology* / Q000378:metabolism*; D000818:Animals; D064032:Calbindin 2; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000378:metabolism; D002766:Cholecystokinin / Q000378:metabolism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D018613:Microscopy, Confocal / Q000379:methods; D009474:Neurons / Q000145:classification / Q000378:metabolism*; D009478:Neuropeptide Y / Q000378:metabolism; D010320:Parvalbumins / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D043562:Receptors, G-Protein-Coupled / Q000172:deficiency / Q000378:metabolism*; D018013:Receptors, Neuropeptide / Q000172:deficiency / Q000378:metabolism*; D064030:S100 Calcium Binding Protein G / Q000378:metabolism; D013004:Somatostatin / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
C576511:Calb2 protein, mouse; C576512:Calb2 protein, rat; D064032:Calbindin 2; D009478:Neuropeptide Y; C066211:Npy1r protein, rat; D010320:Parvalbumins; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide; D064030:S100 Calcium Binding Protein G; D013004:Somatostatin; D005680:gamma-Aminobutyric Acid; D002766:Cholecystokinin; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2